On this page
Which FDA document should you use to change an application’s status?
Start with the current FDA record and the exact object of the change: an IND, pending application or supplement, marketed product, or existing approval or license. Then identify the intended outcome. Withdrawal, inactivation, reinstatement and discontinuation of sales have different procedures; a business decision to stop work does not select the regulatory route.
Before you begin
FDA human-drug and biologic application status changes. The current agency record and precise requested action determine the route.
What you will prepare: A supported status-transition decision and a correctly scoped request.
Read the last operative FDA action first
Collect the latest FDA status letter, any hold or termination order, application approval/licensing evidence and the sponsor’s proposed action. “We stopped development” describes a business event, not a regulatory status.
| Starting situation | Task to investigate |
|---|---|
| Effective IND the sponsor intends to end | Withdrawal under §312.38, heading 1.5.1 |
| IND for which inactive status is appropriate | §312.45 inactivation/reactivation, headings 1.5.2–1.5.3 |
| IND terminated under §312.44(d) | Reinstatement based on eliminating the identified danger, heading 1.5.4 |
| Pending marketing application or supplement | Unapproved withdrawal, heading 1.5.5 |
| Listed drug discontinued from sale | Marketing-status and withdrawal-reason assessment, heading 1.5.6 |
| Approved NDA/ANDA or licensed biologic | Withdrawal of approval/revocation route, heading 1.5.7 |
A clinical hold is another distinct state. Do not label a complete response to hold issues a routine inactive-IND reactivation.
Make the affected scope explicit
Identify whether the request concerns the entire application, one pending supplement, selected products/strengths, or particular investigations. Write a before/after statement and compare it with the intended operational consequences. Removing an application from active development does not erase records, reporting duties or participant-protection responsibilities.
Fictional exercise: a commercial team asks to “withdraw the NDA,” intending only to stop selling one strength. The regulatory owner must distinguish discontinued marketing from withdrawal of approval. If the last agency action is unavailable, the status decision remains undetermined; obtain the record before drafting a definitive request.
Build a before-and-after status record
Use a short decision record before opening a letter template. The record should let a colleague who was absent from the decision meeting understand both the intended action and its limits.
| Field | What to enter | What prevents a reliable decision |
|---|---|---|
| Object | Application number, supplement, product/strength or investigation | A project nickname without controlled identifiers |
| Current state | Status and dated supporting agency record | “Dormant,” “closed” or “cancelled” used only internally |
| Desired outcome | What the sponsor wants FDA or the applicant to do | “Withdraw” without saying what is being withdrawn |
| Procedure | Applicable provision and submission type | Reusing a route from a different starting state |
| Consequences | Studies, stock, reporting and related submissions affected | Assuming that one status change ends every obligation |
| Completion evidence | Notice, receipt, acknowledgement or agency action appropriate to the route | Treating every submission receipt as an agency decision |
Do not force missing information into a yes/no choice. Write “status not established,” identify the missing record and assign its retrieval. This is a drafting control, not an additional FDA requirement. Where records conflict, reconcile the later operative action rather than choosing the document with the most convenient label.
Two-event exercise: a team decides on Monday to abandon a pending supplement. FDA approves it on Tuesday, before the team sends its Wednesday notice. A Monday draft based on pending status no longer describes the starting state. Recheck the approval record, scope and desired action before execution. Keep the underlying business decision; reconsider its regulatory implementation.
For clinical programs, compare IND withdrawal, inactivation and reactivation, and terminated-IND reinstatement. For marketed products, compare withdrawal from sale with withdrawal of approval or license revocation. The links answer different tasks even when the same product appears in each.
Your preparation checklist
0/3 checkedUse this to track your review in this visit. Checks are not saved and do not establish regulatory compliance.
Frequently asked questions
Does stopping development automatically make an IND inactive?
No. A project’s internal status is not FDA inactive status. Section 312.45 describes the circumstances and agency process for inactivation. Establish the actual IND status before changing reporting plans or preparing a restart; absence of enrollment alone does not prove that FDA has placed the IND on inactive status.
Is withdrawal from sale the same as withdrawal of FDA approval?
No. Stopping distribution concerns marketing status, while withdrawal of approval concerns the application’s regulatory authorization. Record the actual product, reason and agency actions separately. A discontinued listing or an applicant’s marketing-status notice should not be used as evidence that FDA has withdrawn approval.
Can a submission acknowledgement prove that every requested status change is complete?
No. Read what the acknowledgement actually establishes and the procedure governing the action. Delivery, receipt, acknowledgement and an agency decision are different events. For example, a terminated IND is not reinstated merely because FDA received additional information; the requisite agency action must be established.
Sources and revisions
Requirements, source recommendations and editorial preparation advice have different roles. Review the scope and revision of the source you use.
Regulation
21 CFR Part 312: IND responsibilities and status ↗Current part reopened September 22, 2026; relevant provisions identified in each section. Regulatory requirements, not a marketing-application rule.
Regulation
21 CFR Part 314: drug marketing applications ↗Current part reopened September 22, 2026; §§314.50, 314.53, 314.65, 314.72, 314.94, 314.99, 314.108 and 314.150–162 inspected. Not a general BLA rule.
Regulation
21 CFR Part 601: biologics licensing ↗Current part reopened September 22, 2026; §§601.5 and 601.9 distinguish revocation and reissuance.
Technical specification · placement only
FDA eCTD v4.0 comprehensive hierarchy ↗Version 2.2, February 2025. Section 1.5. A heading identifies placement, not mandatory applicability.